5th Circuit Affirms Texas’ FDA Defense Law In Abilify Withdrawal Suit
NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals on Oct. 29 affirmed that a pro se plaintiff’s withdrawal injury claim from the atypical antipsychotic Abilify is barred by a...To view the full article, register now.
Already a subscriber? Click here to view full article